1.中山大学附属第一院放射诊断科,广东 广州 510080
2.广州新华学院生物医学工程学院,广东 广州 510080
3.中山大学附属第一医院核医学科,广东 广州 510080
林少春,副主任技师;研究方向:医学影像;E-mail:lshchun@mail.sysu.edu.cn
纸质出版日期:2023-03-20,
收稿日期:2022-11-21,
扫 描 看 全 文
林少春,黎恩廷,陈志丰等.18F-FDG PET/CT预测弥漫大B细胞淋巴瘤化疗后无进展生存期[J].中山大学学报(医学科学版),2023,44(02):262-270.
LIN Shao-chun,LI En-ting,CHEN Zhi-feng,et al.18F-FDG PET/CT Prognostic Role in Diffuse Large B-cell Lymphoma Following Chemotherapy[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(02):262-270.
林少春,黎恩廷,陈志丰等.18F-FDG PET/CT预测弥漫大B细胞淋巴瘤化疗后无进展生存期[J].中山大学学报(医学科学版),2023,44(02):262-270. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20230202.001.
LIN Shao-chun,LI En-ting,CHEN Zhi-feng,et al.18F-FDG PET/CT Prognostic Role in Diffuse Large B-cell Lymphoma Following Chemotherapy[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(02):262-270. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20230202.001.
目的
2
评估
18
F-FDG PET/CT不同代谢参数在分析弥漫性大B细胞淋巴瘤(DLBCL)治疗响应中的预测价值。
方法
2
回顾性地选取2015年6月至2020年10月收治
18
F-FDG PET/CT的81例DLBCL患者。通过多元逻辑回归分析确定DLBCL治疗反应的预测因素,并根据这些因素创建预测模型。之后,通过特性曲线和校准图验证此预测模型的性能。
结果
2
首次化疗后2年内,23例患者(28.3%,23/81)疾病复发,58例患者(71.7%,58/81)无进展。本文分析了PET/CT特征的二元逻辑回归模型的预测能力。结果显示,化疗后
18
F-FDG PET/CT 的定量值是无进展生存期(PFS)的独立预后因素。其中, SUV
THR-mean
2是预测DLBCL患者化疗后治疗反应的最重要因素,临界值为2.00(AUC=0.81)。
结论
2
我们建立的影像学特征预测模型显示出对DLBCL化疗无进展生存期的良好预测效能。其中,化疗后的影像学特征SUV
THR-mean
2是DLBCL患者PSF预后的最佳独立预测因素。我们的预测模型将能提示疾病进展风险,有利于建议临床选择适当的治疗及随访方案,提高诊治效能,节省医疗成本。
Objective
2
To assess the prognostic value of
18
F-FDG PET/CT parameters for predicting therapeutic response in diffuse large B-cell lymphoma (DLBCL).
Methods
2
We retrospectively analyzed the clinical data and
18
F-FDG PET/CT radiomics features of 81 DLBCL patients enrolled between June 2015 and October 2020. Multivariate logistic regression analysis was used to identify the predictive factors for therapeutic response of DLBCL, based on which a predictive model was developed accordingly. The performance of the model was evaluated by receiver operating characteristic (ROC) curves and calibration plots.
Results
2
During the two years after first chemotherapy, 23 patients (28.3%) developed relapse and 58 patients (71.7%) had progression-free survival (PFS). The analysis for the predictive capability of the binary logistic regression model incorporating the PET/CT features revealed that the imaging features of
18
F-FDG PET/CT after chemotherapy were independent prognostic factors for PFS. Among them, SUV
THR-mean
2 was the most important factor for predicting therapeutic response in DLBCL patients after chemotherapy, with a cutoff value of 2.00 (AUC=0.81).
Conclusions
2
18
F-FDG PET/CT showed a valuable prognostic performance for PFS in DLBCL patients after chemotherapy, with the imaging feature after chemotherapy SUV
TLR-mean
2 being the optimal independent predictor. Our predictive model of imaging features might have an important prognostic value in assessing the risk of disease progression, guiding the treatment and follow-up protocol, improving therapeutic efficiency and cutting down the medical cost.
弥漫大B细胞淋巴瘤PET/CT治疗响应预测模型
diffuse large B-cell lymphoma(DLBCL)PET/CTtherapeutic responsepredictive model
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J]. Blood, 2010, 116(12): 2040-2045.
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group[J]. Lancet Oncol, 2006, 7(5): 379-391.
He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma[J]. Leukemia, 2021, 35(8): 2151-2165.
陈婷婷, 张新友, 周继豪. 弥漫大B细胞淋巴瘤的临床及分子分型研究进展[J]. 广东医学, 2022, 43(2): 156-161.
Chen TT, Zhang XY, Zhou JH. Progress in clinical and molecular typing of diffuse large B-cell lymphoma[J]. J Guangdong Med, 2022, 43(2): 156-161.
Cheson BD. PET/CT in lymphoma: current overview and future directions[J]. Semin Nucl Med, 2018, 48(1): 76-81.
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. Blood, 2007, 109(5): 1857-1861.
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014, 123(6): 837-842.
Eisazadeh R, Mirshahvalad SA. 18F-FDG PET/CT prognostic role in predicting response to salvage therapy in relapsed/refractory Hodgkin's lymphoma[J]. Clin Imaging, 2022, 92: 25-31.
Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL[J]. Eur J Nucl Med Mol Imaging, 2016, 43(7): 1209-1219.
Toledano MN, Desbordes P, Banjar A, et al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2018, 45(5): 680-688.
Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET Dissemination features in diffuse large B-cell lymphoma are predictive of outcome[J]. J Nucl Med, 2020, 61(1): 40-45.
Ceriani L, Gritti G, Cascione L, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model[J]. Blood Adv, 2020, 4(6):1082-1092.
张帆, 张国旭, 刘秀婷, 等. (18)F-FDG PET/CT代谢参数及临床指标在弥漫性大B细胞淋巴瘤中期评估及预后预测中的意义[J]. 新医学, 2022, 53(3): 199-203.
Zhang F, Zhang GX, Liu XT, et al. Significance of (18) F-FDG PET/CT metabolic parameters and clinical indicators in the interim evaluation and prognosis prediction of diffuse large B-cell lymphoma[J]. J New Med, 2022, 53(3): 199-203.
Aide N, Fruchart C, Nganoa C, et al. Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy[J]. Eur Radiol, 2020, 30(8): 4623-4632.
Wang XY, Yang WX, Zhou Q, et al. The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49 (12): 4241-4251.
Eertink JJ, Zwezerijnen GJC, Cysouw MCF, et al. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features[J]. Eur J Nucl Med Mol Imaging, 2022, 49 (13): 4642-4651.
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 20[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 328-354.
Eun NL, Kang D, Son EJ, et al. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer[J]. Radiology, 2020, 294(1):31-41.
Park JE, Kim HS, Park SY, et al. Prediction of core signaling pathway by using diffusion- and perfusion-based MRI Radiomics and next-generation sequencing in isocitrate dehydrogenase wild-type glioblastoma[J]. Radiology, 2020, 294(2): 388-397.
Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma[J]. J Clin Oncol, 2017, 35(31): 3529-3537.
Moskowitz CH. Interim PET-CT in the management of diffuse large B-cell lymphoma[J]. Hematology, 2012, 2012: 397-401.
Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography(FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome[J]. Blood, 2005, 106(4): 1376-1381.
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study[J]. J Clin Oncol, 2007, 25(24): 3746-3752.
Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis[J]. J Nucl Med, 2007, 48(10): 1626-1632.
Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2014, 41(11): 2017-2022.
Esfahani SA, Heidari P, Halpern EF, et al. Baseline total lesion glycolysis measured with 18F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study[J]. Am J Nucl Med Mol Imaging, 2013, 3(3): 272-281.
Boellaard R. Standards for PET image acquisition and quantitative data analysis[J]. J Nucl Med, 2009, 50 (S 1):11S-20S.
Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma[J]. Haematologica, 2000, 85(6): 613-618.
Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease[J]. J Nucl Med, 2002, 43(8): 1018-1027.
Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma[J]. Ann Oncol, 2002, 13(9): 1356-1363.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构